Astrazeneca Pharma India Ltd.

Financial

	Astrazeneca Pharma I	Pfizer	Wockhardt
Operational Metrics
Pharmaceutical Sector
Domestic Sales Growth - YoY	18.6 %	7.3 %	10.6 %
R&D as a % of Total Sales	0.0	n/a	4.2 %
Financials
5 yr Average ROE	18.37 %	18.39 %	-3.81 %
5yr average Equity Multiplier	1.94	1.28	2.26
5yr Average Asset Turnover Ratio	0.94	0.6	0.39
5yr Avg Net Profit Margin	10.03 %	24.04 %	-4.46 %
Price to Book	29.18	4.97	6.48
P/E	204.41	30.3	0.0
5yr Avg Cash Conversion Cycle	-36.14 Days	-2.02 Days	-118.47 Days
Inventory Days	64.11 Days	49.44 Days	68.12 Days
Days Receivable	36.53 Days	26.74 Days	71.63 Days
Days Payable	208.62 Days	81.1 Days	260.3 Days
5yr Average Interest Coverage Ratio	140.96	170.95	-0.67
5yr Avg ROCE	23.99 %	23.56 %	-1.45 %
5yr Avg Operating Profit Margin	14.51 %	30.56 %	3.11 %
5 yr average Debt to Equity	0.0	0.0	0.71
5yr CAGR Net Profit	17.47 %	65.36 %	46.24 %
5yr Average Return on Assets	9.52 %	14.39 %	-1.84 %
Shareholdings
Promoter Holding	75.0 %	63.92 %	49.09 %
Share Pledged by Promoters	0.0	0.0	16.98 %
Change in Promoter Holding (3 Yrs)	0.0	0.0	-18.04 %
Change in Mutual Fund Holding (3 Yrs)	4.07 %	3.01 %	7.1 %

Business

	Astrazeneca Pharma I	Pfizer	Wockhardt
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 93.06 Clinical Trial 6.94 Pharmaceutical 0 Pharmaceuticals 0	Product Wise Break-Up Pharmaceutical 100.0 Clinical Trial 0 Pharmaceuticals 0	Product Wise Break-Up Pharmaceutical 0 Clinical Trial 0 Pharmaceutical 100.0
Location Wise Break-Up	Location Wise Break-Up India 93.61 Rest of the World 6.39 Europe 0 USA 0	Location Wise Break-Up Rest of the World 3.86 USA 0 India 96.14 Europe 0	Location Wise Break-Up Rest of the World 10.21 USA 3.45 India 15.72 Europe 24.69 Others 45.93
Therapeutic Area Break-Up	Therapeutic Area Break-Up Oncology 62.3 Cardiac Science 24.4 Anti - Diabetes 9.8 Respiratory Systems 3.5 Gastrointestinal 0 Infection 0	-	-
Dosage Form Break-Up	Dosage Form Break-Up Tablet 67.23 Injectable 24.44 Clinical Trial 6.94 Inhalation 1.39	-	-